Design Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DSGN research report →
Companywww.designtx.com
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs.
- CEO
- Pratik Shah
- IPO
- 2021
- Employees
- 56
- HQ
- Carlsbad, CA, US
Price Chart
Valuation
- Market Cap
- $694.23M
- P/E
- -9.78
- P/S
- 0.00
- P/B
- 3.13
- EV/EBITDA
- -9.32
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -33.07%
- ROIC
- -35.67%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-69,792,000 · -40.74%
- EPS
- $-1.22 · -38.64%
- Op Income
- $-79,467,000
- FCF YoY
- -25.56%
Performance & Tape
- 52W High
- $17.25
- 52W Low
- $3.33
- 50D MA
- $12.28
- 200D MA
- $8.98
- Beta
- 1.74
- Avg Volume
- 548.40K
Get TickerSpark's AI analysis on DSGN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Start Free Trial →Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 31, 26 | Shapiro David | other | 60,000 |
| Mar 31, 26 | Shapiro David | other | 7,500 |
| Mar 31, 26 | Shapiro David | other | 0 |
| Jan 2, 26 | Storgard Chris | other | 250,000 |
| Jan 2, 26 | Jeffries Sean | other | 375,000 |
| Jan 2, 26 | Burgess Julie | other | 150,000 |
| Jan 2, 26 | Gover Justin D. | other | 45,000 |
| Jan 2, 26 | Shah Pratik | other | 750,000 |
| Dec 9, 25 | Shah Pratik | other | 525,000 |
| Sep 9, 25 | Gover Justin D. | other | 30,000 |
Our DSGN Coverage
We haven't published any research on DSGN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate DSGN Report →